These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 24184771

  • 21. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs.
    Peverelli E, Mantovani G, Vitali E, Elli FM, Olgiati L, Ferrero S, Laws ER, Della Mina P, Villa A, Beck-Peccoz P, Spada A, Lania AG.
    J Clin Endocrinol Metab; 2012 Mar; 97(3):967-77. PubMed ID: 22259062
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.
    Huang J, Zhang F, Jiang L, Hu G, Sun W, Zhang C, Ding X.
    Cancer Res Treat; 2017 Apr; 49(2):358-373. PubMed ID: 27488872
    [Abstract] [Full Text] [Related]

  • 23. Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis.
    Jiang YN, Li YH, Ke MW, Tseng TY, Tang YB, Huang MC, Cheng WT, Ju YT.
    Cancer Cell Int; 2007 Mar 02; 7():1. PubMed ID: 17331262
    [Abstract] [Full Text] [Related]

  • 24. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells.
    Kanasaki H, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E.
    Biol Reprod; 2000 Jun 02; 62(6):1486-94. PubMed ID: 10819748
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Experimental study of dually targeting gene therapy system for pituitary adenomas].
    Ma CY, Lu YC, Shi JX, Ren CC, Zhu JD, Gu JR.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 26; 85(4):262-6. PubMed ID: 15854489
    [Abstract] [Full Text] [Related]

  • 27. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
    Xiao Z, Liang J, Deng Q, Song C, Yang X, Liu Z, Shao Z, Zhang K, Wang X, Li Z.
    Int J Mol Med; 2021 Jan 26; 47(1):113-124. PubMed ID: 33155660
    [Abstract] [Full Text] [Related]

  • 28. Either isoform of the dopamine D2 receptor can mediate dopaminergic repression of the rat prolactin promoter.
    McChesney R, Sealfon SC, Tsutsumi M, Dong KW, Roberts JL, Bancroft C.
    Mol Cell Endocrinol; 1991 Aug 26; 79(1-3):R1-7. PubMed ID: 1834494
    [Abstract] [Full Text] [Related]

  • 29. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
    Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A.
    J Neuroendocrinol; 1996 Oct 26; 8(10):737-46. PubMed ID: 8910802
    [Abstract] [Full Text] [Related]

  • 30. Effects of bromocriptine on cell cycle distribution and cell morphology in cultured rat pituitary adenoma cells.
    Johansen PW, Clausen OP, Haug E, Fossum S, Gautvik KM.
    Acta Endocrinol (Copenh); 1985 Nov 26; 110(3):319-28. PubMed ID: 4072574
    [Abstract] [Full Text] [Related]

  • 31. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
    Ben-Shlomo A, Miklovsky I, Ren SG, Yong WH, Heaney AP, Culler MD, Melmed S.
    J Clin Endocrinol Metab; 2003 Feb 26; 88(2):858-63. PubMed ID: 12574225
    [Abstract] [Full Text] [Related]

  • 32. Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: ultrastructural alterations of secretory granules.
    Saitoh Y, Koizumi K, Arita N, Hayakawa T, Mogami H, Matsumoto K, Mori H.
    Anticancer Res; 1986 Feb 26; 6(5):1149-55. PubMed ID: 3800323
    [Abstract] [Full Text] [Related]

  • 33. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W, Riedl M, Luger A, Czech T, Rössler K, Asenbaum S, Angelberger P, Kornhuber J, Deecke L, Podreka I, Brücke T.
    J Nucl Med; 1996 Dec 26; 37(12):1931-7. PubMed ID: 8970508
    [Abstract] [Full Text] [Related]

  • 34. MicroRNA-9 regulates fetal alcohol-induced changes in D2 receptor to promote prolactin production.
    Gangisetty O, Jabbar S, Wynne O, Sarkar DK.
    J Endocrinol; 2017 Oct 26; 235(1):1-14. PubMed ID: 28710248
    [Abstract] [Full Text] [Related]

  • 35. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
    Wu Z, Zheng Y, Xie W, Li Q, Zhang Y, Ren B, Cai L, Cheng Y, Tang H, Su Z, Wu ZB.
    Mol Cell Endocrinol; 2020 Dec 01; 518():111033. PubMed ID: 32946927
    [Abstract] [Full Text] [Related]

  • 36. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
    Jian M, Du Q, Zhu D, Mao Z, Wang X, Feng Y, Xiao Z, Wang H, Zhu Y.
    J Endocrinol Invest; 2019 Jun 01; 42(6):639-652. PubMed ID: 30370446
    [Abstract] [Full Text] [Related]

  • 37. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
    Tang C, Sun R, Wen G, Zhong C, Yang J, Zhu J, Cong Z, Luo X, Ma C.
    Cell Death Dis; 2019 Apr 18; 10(5):335. PubMed ID: 31000722
    [Abstract] [Full Text] [Related]

  • 38. Tamoxifen inhibits GH3 cell growth in culture via enhancement of apoptosis.
    Lee SY, Ahn BT, Baik SH, Lee BL.
    Neurosurgery; 1998 Jul 18; 43(1):116-23. PubMed ID: 9657197
    [Abstract] [Full Text] [Related]

  • 39. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.
    Wu ZB, Zheng WM, Su ZP, Chen Y, Wu JS, Wang CD, Lin C, Zeng YJ, Zhuge QC.
    J Neurooncol; 2010 Aug 18; 99(1):25-32. PubMed ID: 20063113
    [Abstract] [Full Text] [Related]

  • 40. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM, Perez-Millán MI, Ornstein AM, Cristina C, Becu-Villalobos D.
    J Pharmacol Exp Ther; 2011 Jun 18; 337(3):766-74. PubMed ID: 21406548
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.